Economic burden of fungal diseases in the United States

We conservatively estimated the annual US fungal disease-related economic burden as $19.4 billion, including direct medical costs ($13.4 billion) of hospitalizations (n = 133 555) and outpatient visits (n = 13.4 million), $1.7 billion from absenteeism, and $4.3 billion from deaths (n = 7288). These findings underscore the need for fungal disease surveillance, treatment, and prevention efforts.